F. Selcukbiricik Et Al. , "Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer," Clinical and Translational Oncology , vol.18, no.11, pp.1082-1087, 2016
Selcukbiricik, F. Et Al. 2016. Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer. Clinical and Translational Oncology , vol.18, no.11 , 1082-1087.
Selcukbiricik, F., Kanbay, M., Solak, Y., BİLİCİ, A., Kanıtez, M., Balık, E., ... Mandel, N.(2016). Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer. Clinical and Translational Oncology , vol.18, no.11, 1082-1087.
Selcukbiricik, F. Et Al. "Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer," Clinical and Translational Oncology , vol.18, no.11, 1082-1087, 2016
Selcukbiricik, F. Et Al. "Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer." Clinical and Translational Oncology , vol.18, no.11, pp.1082-1087, 2016
Selcukbiricik, F. Et Al. (2016) . "Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer." Clinical and Translational Oncology , vol.18, no.11, pp.1082-1087.
@article{article, author={F. Selcukbiricik Et Al. }, title={Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer}, journal={Clinical and Translational Oncology}, year=2016, pages={1082-1087} }